For questions, or to speak with someone directly, please call:
1-888-824-0200
To request an appointment, please use our secure online form. A representative will contact you within one to two business days to help you schedule an appointment.
Request an AppointmentCurrent patients may also use MyChart to request an appointment.
The patient portal is not for medical emergencies. If you have a medical emergency, call 911.
For help with MyChart, call us at 1-844-442-4278.
For help with Ingalls Care Connection, call us at 1-708-915-4357 or email portalsupport@ingalls.org.
Find a Clinical Trial
A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.
Interventional / Recruiting / NCT02841748
This is a phase 1a/b single-arm, open-label study to evaluate safety, tolerability, PK, and clinical benefit of Cabiralizumab in combination with nivolumab in patients with selected advanced cancers.
Interventional / Recruiting / NCT02526017
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell...
Interventional / Recruiting / NCT02643550
This study will examine the safety profile of SEA-CD40 given alone and in combination with pembrolizumab. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find...
Interventional / Recruiting / NCT02376699
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.
Interventional / Recruiting / NCT02565758
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients...
Interventional / Recruiting / NCT03083873
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.
Interventional / Recruiting / NCT02178722
This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
Interventional / Recruiting / NCT02586987
This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
Interventional / Recruiting / NCT00318890
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Interventional / Recruiting / NCT02741570
